Table 1.
Recent informative trials and results of T-cell-replete haploidentical stem cell transplantation
| Reference, year, ref, and median age | Patients (No.) | Diagnosis | Graft | ANC median (range) | PLT median (range) | GVHD | TRM | Relapse | LFS | OS | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Acute II–IV | Chronic | ||||||||||
| Unmanipulated haplo-SCT with ATG | |||||||||||
| Di Bartolomeo P, et al. [57] (37) | 80 | HM | G-BM | 21 (12–38) | 28 (14–185) | 24 % | 17 % at 2 yr | 36 % at 3 yr | 21 % at 1 yr | 38 % at 3 yr | 45 % at 3 yr |
| Wang Y, et al. [10] (25) | 1210 | HM | G-BM + G-PB | 13 (8–49) | 16 (5–100) | 40 % | 50 % | 17 % at 3 yr | 17 % at 3 yr | 67 % at 3 yr | 70 % at 3 yr |
| Luo Y, et al. [14] (25) | 99 | HM | G-PB | 12 (8–24) | 15 (6–53) | 42.4 % | 41.4 % at 2 yr | 30.5 % at 5 yr | 14.2 % at 5 yr | 58.3 % at 5 yr | 60.8 % at 5 yr |
| Gao L, et al. [66] (25.4) | 26 | SAA | G-PB + G-BM | 13 (11–19) | 13 (10–21) | 8.0 % | 40 % | 15.4 % at 2 yr | NA | NA | 84.6 % at 2 yr |
| Peccatori J, et al. [19] (48) | 121 | HM | G-PB | 17 (11–61) | 19 (7–154) | 35 % | 47 % at 2 yr | 31 % at 3 yr | 48 % at 3 yr | 20 % at 3 yr | 25 % at 3 yr |
| Shin SH, et al. [29] (48) | 60 | MDS | G-PB | 12 (8–23) | 15 (6–132) | 36.7 % | 48.3 % | 23.3 % at 2 yr | 34.8 % at 2 yr | 41.9 % at 2 yr | 46.6 % at 2 yr |
| Yahng SA, et al. [120] (41) | 80 | AML | G-PB | 11 | 10 | 47.5 % | 45 % | 12.2 % at 2 yr | 26.6 % at 2 yr | 61.1 % at 2 yr | 66 % at 2 yr |
| Lin X, et al. [78] (23) | 105 | HM | G-PB | 14 (10–25) | 16 (9–38) | 21.9 % | 24.1 % at 2 yr | 30.5 % at 3 yr | 21.9 % at 3 yr | 41.1 % at 3 yr | 50.6 % at 3 yr |
| TCR haplo-SCT with PT/Cy | |||||||||||
| Raiola AM, et al. [38] (45) | 92 | HM | SS-BM (92) | 18 (11–32) | 32 (5–83) | 14 % | 15 % | 18 % at 1000 days | 35 % | 43 % at 4 yr | 52 % at 4 yr |
| McCurdy SR, et al. [36] (55) | 372 | HM | SS-BM | 90 %a | 88 %b | 32 % at 6 m | 13 % at 2 yr | 11 % at 1 yr | 46 % at 3 yr | 40 % at 3 yr | 50 % at 3 yr |
| Bacigalupo A, et al. [37] (47) | 148 | HM | SS-BM | 17 (13–32) | NA | 18 % | 20 % at 2 yr | 14 % at 4 yr | 27 % at 4 yr | NA | 77 % for CR1 49 % for CR2 38 % for AD |
| Solomon SR, et al. [61] (46) | 30 | HM | G-PB | 16 (NA) | 25 (NA) | 43 % | 56 % | 3 % at 2 yr | 24 % at 2 yr | 73 % at 2 yr | 78 % at 2 yr |
| Cieri N, et al. [64] (55) | 40 | HM | G-PB | 18 (13–45) | 16 (9–100) | 15 % | 20 % at 1 yr | 17 % at 1 yr | 35 % at 1 yr | 48 % at 1 yr | 56 % at 1 yr |
| Esteves I, et al. [65] (17) | 16 | SAA | SS-BM (13) G-PB (3) | 19 (16–29) | 21 (20–29) | 13 % | 20 % | 32.9 % at 1 yr | NA | NA | 67.1 % at 1 yr |
| Ciurea SO, et al. [62] (NA) | 104c | AML | SS-BM (85) G-PB (19) | 90 % | 88 % | 16 % | 30 % at 3 yr | 14 % at 3 yr | 44 % at 3 yr | NA | 45 % at 3 yr |
| 88d | AML | SS-BM (77) G-PB (11) | 93 % | 88 % | 19 % | 34 % at 3 yr | 9 % at 3 yr | 58 % at 3 yr | NA | 46 % at 3 yr | |
| Kasamon YL, et al. [59] (61) | 271 | HM | SS-BM | 88–93 % | 84–89 % | 33 % at 6 m | 12 % at 1 yr | 10 % at 1 yr | 46 % at 3 yr | 37 % at 3 yr | 46 % at 3 yr |
Published between 2013 and 2015
Ref reference, Pts patients, No. number, ANC absolute neutrophil count, PLT platelet, GVHD graft-versus-host disease, TRM transplant-related mortality, LFS leukemia-free survival, OS overall survival, haplo-SCT haploidentical stem cell transplantation, ATG anti-thymocyte globulin, HM hematological malignancies, G-BM granulocyte colony-stimulating factor (G-CSF)-primed bone marrow, yr year, G-PB G-CSF-mobilized peripheral blood stem cell grafts, UCB umbilical cord blood, NA not available, AL acute leukemia, SAA severe aplastic anemia, MDS myelodysplastic syndrome, AML acute myeloid leukemia, PT/Cy posttransplant cyclophosphamide, SS-BM steady-state bone marrow, m months, AD advanced disease
aIndicates the probability of neutrophil recovery by day 30
bIndicates the probability of platelet recovery ≥20,000/μL by day 60
cIndicates that patients received myeloablative conditioning regimens
dIndicates that patients received reduced intensity conditioning regimens